SiriusPoint Q2 EPS $0.37 Beats $0.30 Estimate

SiriusPoint (NYSE:SPNT) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.30 by 23.33 percent.

byBenzinga Newsdesk

August 5, 2021

1 minute read

SiriusPoint (NYSE:SPNT) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.30 by 23.33 percent.

$100 Invested In Cintas 15 Years Ago Would Be Worth This Much Today

By Benzinga Insights

Today, 10:57 PM

Cintas (NASDAQ:CTAS) has outperformed the market over the past 15 years by 9.68% on an annualized basis producing an average annual return of 16.14%. Currently, Cintas has a market capitalization of $38.79 billion.

CTAS

Evercore ISI Group Initiates Coverage On Warby Parker with In-Line Rating, Announces Price Target of $54

By Benzinga Newsdesk

Today, 10:57 PM

Evercore ISI Group analyst Mark Mahaney initiates coverage on Warby Parker (NYSE:WRBY) with a In-Line rating and announces Price Target of $54.

WRBY

Clovis Oncology’s Rubraca Hits Primary Goal In Prostate Cancer Settings

By Vandana Singh

Today, 10:57 PM

Clovis Oncology Inc (NASDAQ:CLVS) announced topline data from the Phase 3 TRITON3 trial, demonstrating that Rubraca monotherapy treatment significantly improved radiographic…

CLVS

Turning Point Q3 EPS $(1.34) Misses $(1.27) Estimate

By Benzinga Newsdesk

Today, 10:57 PM

Turning Point (NASDAQ:TPTX) reported quarterly losses of $(1.34) per share which missed the analyst consensus estimate of $(1.27) by 5.51 percent. This is a 219.05 percent decrease over losses of $(0.42) per share from

TPTX

SiriusPoint Q2 EPS $0.37 Beats $0.30 Estimate

Related Posts

$100 Invested In Cintas 15 Years Ago Would Be Worth This Much Today

Evercore ISI Group Initiates Coverage On Warby Parker with In-Line Rating, Announces Price Target of $54

Clovis Oncology’s Rubraca Hits Primary Goal In Prostate Cancer Settings

Turning Point Q3 EPS $(1.34) Misses $(1.27) Estimate